| Investor Relations HomeIRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market.
The Company was incorporated in California in February 1989 as IRIS Medical Instruments, Inc. In November 1995, we changed our name to IRIDEX Corporation and reincorporated in Delaware. Investors and others should note that we announce material financial information to our investors using SEC filings, press releases, our investor relations website, public conference calls and webcasts. We use these channels as well as social media to communicate with investors, customers and the public about our company, our products and other issues. It is possible that the information we post on social media channels could be deemed to be material information. We encourage investors, our customers, and others interested in our company to review the information we post on our Facebook page (www.facebook.com/IRIDEX) and Twitter feed (https://twitter.com/IRIDEX).
|  | |
|
| Date | Title | | | 06/11/13 | IRIDEX Announces Automatic Conversion of Series A Preferred Stock to Common Stock| MOUNTAIN VIEW, Calif., June 11, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced that it has converted all outstanding shares of its Series A Preferred Stock into 1,000,000 shares of its common stock. The Series A Preferred shares were issued to BlueLine Capital Partners LP (BlueLine) as part of a private placement agreement that occurred in 2007. The Certificate of Designation provides that the Series A Preferred shares will automatically convert into c... |
|  | | 05/16/13 | IRIDEX Receives Final $510,000 From Sale Of Aesthetic Business Unit| Funds Released from Escrow Account Marks Final Chapter in Sale
MOUNTAIN VIEW, Calif., May 16, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today announced that it has received the final $510,000 cash payment from the February 2012 sale of its aesthetic business unit. The cash was released to IRIDEX from an escrow account set up as part of the transaction.
"The release of the funds from escrow marks the final chapter in the sale of our aesthetics business," said IRIDEX Presi... |
| | | 05/02/13 | IRIDEX Reports 2013 First Quarter Results| Profits Increase as Commercial Progress and Operational Streamlining Continue
MOUNTAIN VIEW, Calif., May 2, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended March 30, 2013.
Ophthalmology revenues in the first quarter were $8.9 million, a first quarter record, compared to $8.3 million in the prior year period.
Gross margin for the first quarter was 47.3%, compared to 48.0% in the prior year period. Margins were impacted... |
| | | 04/30/13 | IRIDEX Announces Receipt of Large Orders for Laser Systems from Developing Countries| Orders from BRIC Countries Demonstrate Cost, Durable Therapeutic Advantages of Laser-Based Treatments for Ophthalmologic Diseases
MOUNTAIN VIEW Calif., April 30, 2013 /PRNewswire/ -- IRIDEX Corporation (Nasdaq:IRIX) today announced that it has recently received two significant orders for its proprietary laser-based medical systems for the treatment of eye diseases. The orders, totaling more than $500,000, are indicative of the burgeoning growth of the ophthalmology market in the "BRIC" econom... |
| |
|
|
| Primary IR Contact | Jim Mackaness
Chief Financial Officer and Chief Operating Officer
Phone: 650-605-8716
E-mail: jmackaness@iridex.com |
| | | | | |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
